Cannabis use is associated with increased psychotic symptoms and poorer psychosocial functioning in first-episode psychosis: A report from the UK National EDEN study

Schizophrenia Bulletin

Volumn 42, Issue 3, 2016, Pages 619-625

  Seddon, Jennifer L ^a   Birchwood, Max ^b   Copello, Alex ^c,d   Everard, Linda ^d   Jones, Peter B ^e   Fowler, David ^f   Amos, Tim ^g   Freemantle, Nick ^h   Sharma, Vimal ^i,j   Marshall, Max ^k   Singh, Swaran P ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d BIRMINGHAM AND SOLIHULL MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f UNIVERSITY OF SUSSEX   (United Kingdom)

^g UNIVERSITY OF BRISTOL   (United Kingdom)

^h ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

ⁱ CHESHIRE AND WIRRAL PARTNERSHIP NHS FOUNDATION TRUST   (United Kingdom)

^j UNIVERSITY OF CHESTER   (United Kingdom)

^k UNIVERSITY OF MANCHESTER   (United Kingdom)

more..

Author keywords

cannabis use; first episode psychosis; prospective study; psychotic symptoms

Indexed keywords

ADULT; ARTICLE; CALGARY DEPRESSION SCALE; CANNABIS USE; COHORT ANALYSIS; DEMOGRAPHY; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; EARLY INTERVENTION; ETHNICITY; FEMALE; GLOBAL ASSESSMENT OF FUNCTIONING; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIA; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; SOCIAL PSYCHOLOGY; SUBSTANCE USE; UNITED KINGDOM; YOUNG MANIA RATING SCALE; ADOLESCENT; FOLLOW UP; PATHOPHYSIOLOGY; PROCEDURES; PSYCHOSES, SUBSTANCE-INDUCED; PSYCHOTIC DISORDERS; YOUNG ADULT;

CANNABIS;

ADOLESCENT; ADULT; CANNABIS; EARLY MEDICAL INTERVENTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOSES, SUBSTANCE-INDUCED; PSYCHOTIC DISORDERS; UNITED KINGDOM; YOUNG ADULT;

EID: 84966293203     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbv154     Document Type: Article

References (44)

1. van Os J, Kapur S. Schizophrenia. Lancet. 2009; 374: 635-645
2. Birchwood M, Todd J, Jackson C. Early intervention in psychosis: the critical period hypothesis. Br J Psychiatry. 1998; 172: 53-59
3. Eaton WW, Thara R, Federman B, Melton B, Liang KY. Structure and course of positive and negative symptoms in schizophrenia. Arch Gen Psychiatry. 1995; 52: 127-134
4. McGlashan TH. Early detection and intervention in schizophrenia: research. Schizophr Bull. 1996; 22: 327-345
5. Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients. Arch General Psychiatry 2005; 62: 975-983
6. Green B, Young R, Kavanagh D. Cannabis use and misuse prevalence among people with psychosis. Br J Psychiatry. 2005; 187: 306-313
7. Baeza I, Graell M, Moreno D, et al. Cannabis use in children and adolescents with first episode psychosis: influence on psychopathology and short-Term outcome (CAFEPS study). Schizophr Res. 2009; 113: 129-137
8. Barnett JH, Werners U, Secher SM, et al. Substance use in a population-based clinic sample of people with first-episode psychosis. Br J Psychiatry. 2007; 190: 515-520
9. Gonzalez-Pinto A, Alberich S, Barbeito S, et al. Cannabis and first-episode psychosis: different long-Term outcomes depending on continued or discontinued use. Schizophr Bull. 2011; 37: 631-639
10. Harrison I, Joyce EM, Mutsatsa SH, et al. Naturalistic follow-up of co-morbid substance use in schizophrenia: the West London first-episode study. Psychol Med. 2008; 38: 79-88
11. Stone JM, Fisher HL, Major B, et al. Cannabis use and first-episode psychosis: relationship with manic and psychotic symptoms, and with age at presentation. Psychol Med. 2014; 44: 499-506
12. Tosato S, Lasalvia A, Bonetto C, et al. The impact of cannabis use on age of onset and clinical characteristics in first-episode psychotic patients. Data from the psychosis Incident cohort outcome study (PICOS). J Psychiatr Res. 2013; 47: 438-444
13. Yucel M, Bora E, Lubman DI, et al. The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-Analysis of existing findings and new data in a firstepisode sample. Schizophr Bull. 2012; 38: 316-330
14. Addington J, Addington D. Patterns, predictors and impact of substance use in early psychosis: a longitudinal study. Acta Psychiatr Scand. 2007; 115: 304-309
15. Grech A, Van Os J, Jones PB, Lewis SW, Murray RM. Cannabis use and outcome of recent onset psychosis. Eur Psychiatry. 2005; 20: 349-353
16. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry. 1994; 51: 273-279
17. Hides L, Dawe S, Kavanagh DJ, Young RM. Psychotic symptom and cannabis relapse in recent-onset psychosis. Br J Psychiatry. 2006; 189: 137-143
18. Clausen L, Hjorthoj CR, Thorup A, et al. Change in cannabis use, clinical symptoms and social functioning among patients with first-episode psychosis: a 5-year follow-up study of patients in the OPUS trial. Psychol Med. 2014; 44: 117-126
19. Large M, Sharma S, Compton MT, Slade T, Nielssen O. Cannabis use and earlier onset of psychosis. Arch Gen Psychiatry. 2011; 68: 555-561
20. Zammit S, Moore TH, Lingford-Hughes A, et al. Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry. 2008; 193: 357-363
21. Green AI, Tohen MF, Hamer RM, et al. First-episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res. 2004; 66: 125-136
22. Schimmelmann BG, Conus P, Cotton S, Kupferschmid S, McGorry PD, Lambert M. Prevalence and impact of cannabis use disorders in adolescents with early onset first episode psychosis. Eur Psychiatry. 2012; 27: 463-469
23. Bally N, Zullino D, Aubry JM. Cannabis use and first manic episode. J Affect Disord. 2014; 165: 103-108
24. Birchwood M, Lester H, McCarthy L, et al. The UK national evaluation of the development and impact of Early Intervention Services (the National EDEN studies): study rationale, design and baseline characteristics. Early Interv Psychiatry. 2014; 8: 59-67
25. Kavanagh D, Saunders J, Young R, Jenner L, Claire A. A Start Over and Survive Treatment Manual: Evaluation of a Brief Intervention for Substance Abuse in Early Psychosis. Brisbane, Australia: University of Queensland; 1998
26. Kavanagh DJ, Trembath M, Shockley N, et al. The DrugCheck Problem List: a new screen for substance use disorders in people with psychosis. Addict Behav. 2011; 36: 927-932
27. Gossop M, Darke S, Griffiths P, et al. The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction. 1995; 90: 607-614
28. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13: 261-276
29. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978; 133: 429-435
30. Addington D, Addington J, Maticka-Tyndale E. Specificity of the Calgary Depression Scale for schizophrenics. Schizophr Res. 1994; 11: 239-244
31. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976; 33: 766-771
32. Jones SH, Thornicroft G, Coffey M, Dunn G. A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry. 1995; 166: 654-659
33. Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics. 1997; 53: 983-997
34. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974; 19: 716-723
35. White IR, Carlin JB. Bias and efficiency of multiple imputation compared with complete-case analysis for missing covariate values. Stat Med. 2010; 29: 2920-2931
36. Opler LA, Opler MA, Malaspine D. Reducing guesswork in schizophrenia treatment: PANSS can target and gauge therapy, predict outcomes. Curr Psychiatry. 2006; 5: 76-84
37. Linszen D, Peters B, de Haan L. Cannabis abuse and the course of schizophrenia. In: Castle D, Murray R, eds. Marijuana and Madness. Cambridge, MA: Cambridge University Press; 2004: 119-126
38. Turkington A, Mulholland CC, Rushe TM, et al. Impact of persistent substance misuse on 1-year outcome in first-episode psychosis. Br J Psychiatry. 2009; 195: 242-248
39. Wolford GL, Rosenberg SD, Drake RE, et al. Evaluation of methods for detecting substance use disorder in persons with severe mental illness. Psychol Addict Behav. 1999; 13: 313-326
40. Fergusson DM, Horwood LJ, Ridder EM. Tests of causal linkages between cannabis use and psychotic symptoms. Addiction. 2005; 100: 354-366
41. Fowler IL, Carr VJ, Carter NT, Lewin TJ. Patterns of current and lifetime substance use in schizophrenia. Schizophr Bull. 1998; 24: 443-455
42. Green B, Kavanagh DJ, Young RM. Reasons for cannabis use in men with and without psychosis. Drug Alcohol Rev. 2004; 23: 445-453
43. Schaub M, Fanghaenel K, Stohler R. Reasons for cannabis use: patients with schizophrenia versus matched healthy controls. Aust N Z J Psychiatry. 2008; 42: 1060-1065
44. Mullin K, Gupta P, Compton MT, Nielssen O, Harris A, Large M. Does giving up substance use work for patients with psychosis? A systematic meta-Analysis. Aust N Z J Psychiatry. 2012; 46: 826-839